New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM
- Resource Type
- Source
- Digestive and Liver Disease. 53:S16
- Subject
medicine.medical_specialty Hepatology business.industry Gastroenterology Antiviral therapy medicine.disease New onset Chronic hepatitis Liver stiffness Internal medicine medicine In patient Steatosis business Hepatic fibrosis Direct acting - Language
- ISSN
- 1590-8658